Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants von Mukai, Yuji, Narita, Masayuki, Akiyama, Erika, Ohashi, Kanami, Horiuchi, Yasutaka, Kato, Yuka, Toda, Takaki, Rane, Anders, Inotsume, Nobuo

Volltext

Metabolically inducing defects in DNA repair sensitizes BRCA -wild-type cancer cells to replication stress von Watanabe, Kenji, Yamamoto, Tatsuro, Fujita, Tomoko, Hino, Shinjiro, Hino, Yuko, Yamazaki, Kanami, Ohashi, Yoshimi, Sakuraba, Shun, Kono, Hidetoshi, Nakao, Mitsuyoshi, Ochiai, Koji, Dan, Shingo, Saitoh, Noriko

Volltext

Abstract 384: Identification of a lung adenocarcinoma cell line addicted to ERBB4, an actionable target for cancer therapy von Tanaka, Noritaka, Yamazaki, Kanami, Uno, Yuko, Ohashi, Yoshimi, Nishimura, Yumiko, Sawa, Masaaki, Dan, Shingo

Volltext

AMF-26, a Novel Inhibitor of the Golgi System, Targeting ADP-ribosylation Factor 1 (Arf1) with Potential for Cancer Therapy von Ohashi, Yoshimi, Iijima, Hiroshi, Yamaotsu, Noriyuki, Yamazaki, Kanami, Sato, Shigeo, Okamura, Mutsumi, Sugimoto, Kenji, Dan, Shingo, Hirono, Shuichi, Yamori, Takao

Volltext

Home transfusions are implemented using diverse approaches in Japan von Tanaka, Asashi, Fujita, Hiroshi, Ohashi, Kota, Tsujikawa, Akihito, Uchiyama, Kanami, Ito, Tatsuya, Kawashima, Koichiro, Kodama, Reiko, Mine, Takashi, Okuda, Makoto, Endoh, Teruo, Fukuyoshi, Youko, Kitazawa, Junichi, Sueoka, Eisaburo, Nagai, Kazuhiro, Ishida, Akaru, Matsuzaki, Koji, Kato, Yoko, Takanashi, Kazuo, Takahashi, Koki

Volltext

Management system of home transfusion in Japan: A nationwide survey in 2019 von Tanaka, Asashi, Fujita, Hiroshi, Ohashi, Kota, Tsujikawa, Akihito, Uchiyama, Kanami, Ito, Tatsuya, Kawashima, Koichiro, Kodama, Reiko, Mine, Takashi, Okuda, Makoto, Endoh, Teruo, Fukuyoshi, Youko, Kitazawa, Junichi, Sueoka, Eisaburo, Nagai, Kazuhiro, Ishida, Akaru, Matsuzaki, Koji, Kato, Yoko, Takanashi, Kazuo, Takahashi, Koki

Volltext

Abstract LB-357: Identification of a new inhibitor of the Golgi system, targeting ADP-ribosylation Factor 1 (Arf1) with potential for cancer therapy von Ohashi, Yoshimi, Iijima, Hiroshi, Yamaotsu, Noriyuki, Yamazaki, Kanami, Sato, Shigeo, Okamura, Mutsumi, Sugimoto, Kenji, Dan, Shingo, Hirono, Shuichi, Yamori, Takao

Volltext